This is a working overview of trans-3-hexenoyl, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-02-21. Anything still debated is marked as such rather than presented as settled.
The native hormone is produced in the hypothalamus and acts on the anterior pituitary. Binding of GHRH to its receptor stimulates synthesis and release of growth hormone into circulation. Because the analogue retains the receptor-binding region of the parent sequence, it engages the same receptor and triggers the same downstream signaling. The result is increased growth hormone secretion from pituitary cells, which in turn influences hepatic production of insulin-like growth factor 1. This axis is the basis for the compound's measured biological effects.
Interest in this peptide developed because native GHRH has a short circulating lifetime. The N-terminal modification slows cleavage by dipeptidyl peptidase IV, an enzyme that removes the first two residues of many peptides and terminates their activity. Slower degradation means a longer window of receptor stimulation per administration. This design logic parallels other modified peptide hormones, where a small chemical change at a vulnerable site yields a more durable molecule without altering the core mechanism of action.
Tesamorelin binds to growth hormone-releasing hormone receptors on somatotroph cells in the anterior pituitary. Receptor activation increases intracellular cyclic AMP and promotes synthesis and secretion of growth hormone. Because the peptide mimics endogenous GHRH, it amplifies the normal pulsatile release of growth hormone rather than providing exogenous growth hormone directly. This upstream action distinguishes tesamorelin from recombinant growth hormone preparations and from growth hormone secretagogues that act at different receptors.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C221H366N72O67S | Reflects a 44-residue peptide with one N-terminal modification |
| Approximate molecular weight | 5136 Da | Sequence length and single acyl group determine the mass |
| Appearance | White to off-white lyophilized powder | Typical form of a purified synthetic peptide |
| Solubility class | Soluble in water and aqueous buffer | Peptide backbone favors aqueous dissolution |
| Common synonyms | GHRH(1-44) analogue; Egrifta | Descriptive name and approved brand name |
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
Lyophilized material is typically held under refrigeration between two and eight degrees Celsius, shielded from light and ambient moisture. Peptides of this size adsorb to glass and plastic, so working procedures often call for low-binding containers and as few transfers as possible. Absorbed water during weighing shifts the apparent mass of a sample, and controlling room humidity reduces that source of error. Once dissolved, solutions are kept cold and used within the interval printed on the accompanying label or certificate. Degradation accelerates markedly in dilute aqueous form.
Identity and purity are judged through a combination of chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the intact peptide from truncated, oxidized, and deamidated variants, and the resulting peak-area percentages yield a purity figure. Electrospray ionization mass spectrometry confirms the expected molecular mass and can expose unanticipated modifications. Amino acid analysis and peptide mapping support sequence fidelity, while water content, pH, sterility, and bacterial endotoxin testing describe the physical and microbiological attributes of a finished lot.
Tesamorelin is a synthetic peptide built from 44 amino acids and classified with the growth hormone–releasing hormone family. Its sequence corresponds to the human GHRH(1-44) backbone, carrying one structural change at the amino terminus. That change is a trans-3-hexenoyl group placed where the natural peptide would have an unmodified end. The modification is the feature that separates the compound from the endogenous hormone in name, in stability, and in how it is handled in the laboratory.
The hexenoyl cap slows the enzyme step that trims the amino terminus of native GHRH, the same step that shortens its active lifetime in circulation. As a result, the modified peptide persists longer in plasma than the unmodified hormone in side-by-side comparison. Receptor activity stays broadly comparable, because the added group sits away from the residues that contact the binding site. This combination, preserved receptor activity with reduced degradation, explains why the analog was developed instead of the native sequence.
Infants can be infected during passage through the birth canal; nevertheless, newborns who acquire GBS through this route may only become colonized, and these colonized infants typically do not develop EOD. Roughly 50% of newborns to GBS colonized mothers are also GBS colonized, and (without prevention measures) 1–2% of these newborns will develop EOD. In the past, the incidence of EOD ranged from 0.7 to 3.7 per thousand live births in the US and from 0.2 to 3.25 per thousand in Europe.Multistate surveillance 2006-2015 shows a decline in EOD from 0.37 to 0.23 per 1000 live births in the US, but LOD remains steady at 0.31 per 1000 live births. In 2021 had been estimated a total of 1970 deaths (0.59/100,000 population) in the US were estimated to be caused by GBS neonatal infections. It was estimated that 226 infants (49 per 100,000) in the United States had a clinically significant GBS infection, and that approximately 11 (2.4%) of those cases resulted in death. The widespread use of intrapartum antibiotic prophylaxis (IAP) has resulted in a decline in the incidence of early neonatal GBS infection in the United States of more than 85%, from 1.8‰ of cases in live births in the 1990s to 0.23‰ in 2015, and to 0.18‰ in 2023.
=== Dekarangers === The eponymous Dekarangers are members of the S.P.D.'s Earth unit who protect Earth from intergalactic criminals called Alienizers. Each of the primary members possess an SP License (SPライセンス, Esu Pī Raisensu) device, which allows them to transform via Change Mode (チェンジモード, Chenji Mōdo); communicate with each other, analyze items pertaining to a case they are working on, and summon their Deka Machines to battle Kaijuki via Phone Mode (フォンモード, Fon Mōdo); and determine a criminal's innocence in a particular crime and whether or not they can be approved for deletion via Judgement Mode (ジャッジメントモード, Jajjimento Mōdo). While transformed, they each carry a varying pair of D-Arms (ディーアームズ, Dī Āmuzu) sidearms, which can combine to form a firearm-like weapon. They also ride varying Deka Vehicles (デカビークル, Deka Bīkuru) for transportation. After undergoing further training, the primary Dekarangers gain the ability to assume S.W.A.T. Mode (スワットモード, Suwatto Mōdo), which clads them in armor that grants heat-seeking, X-ray, and night vision capabilities. They also wield high-powered D-Revolver (ディーリボルバー, Dī Riborubā) machine guns.
=== Oral GLP-1 Semaglutide Generic === SCD has been developing an oral generic version of semaglutide, the active ingredient in Novo Nordisk's Wegovy and Ozempic. In January 2026, SCD signed a partnership agreement with Daiichi Sankyo Espha, a subsidiary of Japan's Daiichi Sankyo, for the exclusive sale of oral semaglutide generics in Japan. Some industry observers and analysts have questioned the company's public statements regarding this product. A commentary published by the Korea Biomedical Review in July 2025 noted that SCD's claims of a potential 2026 market launch for its oral semaglutide generic appeared to overstate the company's regulatory position, given that secondary patents on semaglutide formulations are widely expected to remain in force until at least 2031 in most major markets.
Sources: en.wikipedia.org
Glutathione has antioxidant properties since the thiol group in its cysteine moiety is a reducing agent and can be reversibly oxidized and reduced. In cells, glutathione is maintained in the reduced form by the enzyme glutathione reductase and in turn reduces other metabolites and enzyme systems, such as ascorbate in the glutathione-ascorbate cycle, glutathione peroxidases and glutaredoxins, as well as reacting directly with oxidants. Due to its high concentration and its central role in maintaining the cell's redox state, glutathione is one of the most important cellular antioxidants. In some organisms glutathione is replaced by other thiols, such as by mycothiol in the Actinomycetes, bacillithiol in some gram-positive bacteria, or by trypanothione in the Kinetoplastids. A derivative of glutathione, glutathione hydropersulfide, operates as an abundant radical-trapping antioxidant with greater potency against free radical oxidation than glutathione itself.
==== MeSH E05.196.309 – crystallography ==== MeSH E05.196.309.555 – neutron diffraction MeSH E05.196.309.711 – powder diffraction MeSH E05.196.309.742 – x-ray diffraction MeSH E05.196.309.742.225 – crystallography, x-ray
After the passage of the Morrill Land-Grant Act of 1862, the push for a university in Arizona grew. The Arizona Territory's "Thieving Thirteenth" Legislature approved the University of Arizona in 1885 and selected the city of Tucson to receive the appropriation to build the university. Tucson hoped to receive the appropriation for the territory's mental hospital, which carried a $100,000 allocation instead of the $25,000 allotted to the territory's only university (Arizona State University was also chartered in 1885, but it was created as Arizona's normal school, and not a university). Flooding on the Salt River delayed Tucson's legislators, and by they time they reached Prescott, back-room deals allocating the most desirable territorial institutions had been made. Tucson was largely disappointed with receiving what was viewed as an inferior prize. With no parties willing to provide land for the new institution, the citizens of Tucson prepared to return the money to the Territorial Legislature until two gamblers and a saloon keeper decided to donate 40 acres to the Board of Regents. Construction of Old Main, the first building on it, began on October 27, 1887, and classes met for the first time in 1891 with 32 students in Old Main, which is still in use today. Because there were no high schools in Arizona Territory, the university maintained separate preparatory classes for the first 23 years of operation. In 1924, during Cloyd Marvin's tenure as president, the university was recognized by the Association of American Universities.
Sources: en.wikipedia.org
== Education == Bry received her bachelor's degree in Genetics and Development from Cornell University, then entered the Medical Scientist Training Program at Washington University School of Medicine in St. Louis. She was the first microbiology graduate student of Dr. Jeffrey I. Gordon and used her background in microbiology and microbial genetics to develop novel systems for studying host-microbial cross-talk within the gastrointestinal tract. She was awarded her MD and a PhD in Molecular Microbiology and Pathogenesis in 1998. She subsequently entered the residency program in Clinical Pathology at Brigham and Women's Hospital. While in her second year of the residency program, she was awarded a Howard Hughes Research Fellowship for Physicians to pursue a postdoctoral fellowship in molecular immunology in the laboratory of Dr. Michael B. Brenner at Brigham and Women's Hospital.
=== Other common diseases === EpiVacCorona, a peptide-based vaccine against COVID-19. IC41 is a peptide vaccine candidate against the Hepatitis C virus. It consists of five synthetic peptides along with the synthetic adjuvant called poly-l-arginine. Multimeric-001 is the most efficient peptide vaccine candidate against influenza. It contains B- and T-cell epitopes from Hemagglutinin. Matrix I and nucleoprotein are combined into a single recombinantly-expressed polypeptide. Alzheimer peptide vaccines: CAD106, UB311, Lu, AF20513, ABvac40, ACI-35, AADvac-1.
Epidermolysis bullosa acquisita, also known as acquired epidermolysis bullosa, is a longterm autoimmune blistering skin disease. It generally presents with fragile skin that blisters and becomes red with or without trauma. Marked scarring is left with thin skin, milia and nail changes. It typically begins around age 50. It is caused by antibodies to type VII collagen within anchoring fibril structures located at the dermoepidermal junction in skin. Damaged skin may become infected. Diagnosis is by observing the persistence of the condition, direct immunofluorescence, and detecting autoantibodies against type VII collagen. It can appear similar to porphyria cutanea tarda, pemphigoid, pemphigus, dermatitis herpetiformis, or blistering drug eruption. The condition is longterm and has no cure. A good response may be seen with corticosteroids, either alone or combined with azathioprine or dapsone. It is rare, with around 0.08 to 0.5 new cases per million people per year, and it affects males and females equally.
Sources: en.wikipedia.org
It shares the 44-residue sequence of human GHRH but carries an added trans-3-hexenoyl group at its N-terminus. That addition does not occur in the natural hormone and serves mainly to resist enzymatic breakdown. The receptor target and signaling pathway remain the same.
It binds the growth hormone-releasing hormone receptor on anterior pituitary cells. Activation of that receptor promotes synthesis and release of growth hormone. The effect propagates through the growth hormone and insulin-like growth factor 1 axis.
Native GHRH is cleared quickly by peptidases, which limits how long it can stimulate its receptor. The added group hinders one of the primary cleavage enzymes. The practical consequence is a longer period of receptor activity per dose.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.